Praluent and Metformin Interaction: What You Need to Know
HealthRX.com
No Praluent-metformin interaction in either label
Key numbers
- 75 mgPraluent adult starting dose: 75 mg every 2 weeks, or 300 mg every 4 weeks by injectionSource: accessdata.fda.gov, as cited Nov 7, 2026
- 30 mL/min/1.73 m2Metformin kidney limit: contraindicated when eGFR falls below this valueSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 850 mgMetformin 850 mg tablet taken with food: peak level about 40% lowerSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
FDA adverse event reports listing both alirocumab and metformin
Through 2026-10-28, FDA had received 632 adverse event reports that list both alirocumab and metformin, out of 25,784 reports for alirocumab and 366,420 for metformin. A joint report shows both were recorded for the same person, not that they interacted.
| Measure | Value |
|---|---|
| Reports listing both drugs | 632 |
| All reports for alirocumab | 25,784 |
| All reports for metformin | 366,420 |
| Joint reports naming myalgia | 42 |
| Joint reports naming nausea | 36 |
| Joint reports naming arthralgia | 35 |
| Joint reports naming muscle spasms | 34 |
How this was calculated
Counted FAERS reports that list both active substances in any role, then the symptom terms named most often in those reports. Terms about product use rather than symptoms were left out. The events may relate to either drug, to another drug, or to the illness.
Reports listing both alirocumab and metformin as single-ingredient active substances, any brand, suspect or concomitant
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs. Joint reports are not evidence of an interaction.
At a glance
- Interaction described in either label / None described [1][2]
- Alirocumab handling / Protein expected to degrade to small peptides and amino acids; statin levels unchanged in clinical studies [1]
- Metformin handling / Not metabolized; excreted unchanged by the kidneys [2]
- Dose change for the pair / None described in either label [1][2]
- Metformin interactions that do matter / Carbonic anhydrase inhibitors, OCT2/MATE inhibitors, alcohol, insulin and secretagogues, iodinated contrast [2]
- Praluent's only warning / Hypersensitivity reactions; no boxed warning [1]
What the two labels actually say
Praluent is a human monoclonal antibody against PCSK9. The label starts adults at 75 mg every 2 weeks or 300 mg every 4 weeks by subcutaneous injection, with adjustment to 150 mg every 2 weeks if the LDL cholesterol response is inadequate [1]. Metformin hydrochloride immediate-release tablets are an oral biguanide labeled as an adjunct to diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes [2].
The metformin label's drug interaction table names carbonic anhydrase inhibitors (topiramate, zonisamide, acetazolamide, dichlorphenamide), drugs that reduce metformin clearance through OCT2 and MATE transporters (ranolazine, vandetanib, dolutegravir, cimetidine), alcohol, insulin and insulin secretagogues, and drugs that raise blood glucose [2]. No monoclonal antibody appears in that table.
The Praluent label's interaction information is about statins. In clinical studies of alirocumab with atorvastatin or rosuvastatin there were no relevant changes in statin concentrations, which indicates that CYP enzymes (mainly CYP3A4 and CYP2C9) and transporters such as P-gp and OATP were not affected [1]. The label describes alirocumab as a protein expected to degrade to small peptides and amino acids, and says no specific metabolism studies were done [1].
How each drug is handled in the body
After a subcutaneous dose, alirocumab reaches peak concentrations in a median of 3 to 7 days, has an absolute bioavailability of about 85%, and has a median half-life at steady state of 17 to 20 days [1]. Age, body weight, sex, race and creatinine clearance did not significantly change its pharmacokinetics across 2,799 patients [1].
Metformin has 50% to 60% oral bioavailability. It is not metabolized, is negligibly bound to plasma proteins, and is excreted unchanged in urine, with a renal clearance about 3.5 times creatinine clearance and a plasma half-life of about 6.2 hours [2]. An 850 mg tablet taken with food has a peak concentration about 40% lower and total exposure about 25% lower [2].
Evidence for the pair
Neither label reports a study that gave alirocumab and metformin together and measured drug levels or outcomes, so the available information is what each label says separately.
The largest alirocumab trial, ODYSSEY OUTCOMES, enrolled 18,924 adults who had an acute coronary syndrome 1 to 12 months earlier, with LDL cholesterol of 70 mg/dL or higher on high-intensity or maximally tolerated statin therapy. Over a median 2.8 years, the primary composite of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke or unstable angina requiring hospitalization occurred in 9.5% of those on alirocumab versus 11.1% on placebo (HR 0.85, 95% CI 0.78 to 0.93) [3]. It compared alirocumab with placebo for cardiovascular outcomes and was not an interaction study.
What to watch for on each drug
Alirocumab carries no boxed warning. Its only Warning and Precaution is hypersensitivity, including hypersensitivity vasculitis, angioedema, and reactions requiring hospitalization; the label says to stop treatment and treat if serious symptoms occur [1]. A history of a serious hypersensitivity reaction to alirocumab or an excipient is a contraindication [1]. In nine adult placebo-controlled trials (2,476 on Praluent versus 1,276 on placebo, median 65 weeks), injection site reactions occurred in 7% versus 5%, influenza in 6% versus 5%, diarrhea in 5% versus 4%, and myalgia in 4% versus 3% [1].
Metformin carries a boxed warning for lactic acidosis, with postmarketing cases that included death, hypothermia, hypotension and resistant bradyarrhythmias, and a subtle onset of malaise, myalgias, respiratory distress, somnolence or abdominal pain [4]. The label lists risk factors including renal impairment, carbonic anhydrase inhibitors, age 65 or older, radiologic studies with contrast, surgery, hypoxic states such as acute congestive heart failure, excessive alcohol intake and hepatic impairment [4]. The label also warns about vitamin B12: subnormal levels developed in approximately 7% of patients in 29-week trials, and the label says to measure hematologic parameters annually and vitamin B12 at 2 to 3 year intervals [2]. Digestive side effects are the common ones: in a US trial of 141 patients on metformin up to 2,550 mg daily versus 145 on placebo, diarrhea occurred in 53% versus 12% and nausea or vomiting in 26% versus 8% [2].
Metformin interactions that matter more than this pair
Carbonic anhydrase inhibitors frequently lower serum bicarbonate and can cause non-anion gap acidosis; the label says that using them with metformin may increase the risk of lactic acidosis and suggests more frequent monitoring [2]. Drugs that interfere with OCT2/MATE transport, such as ranolazine, vandetanib, dolutegravir and cimetidine, could raise metformin exposure, and the label says to consider the benefits and risks of using them together [2]. The label states that alcohol potentiates metformin's effect on lactate metabolism and says to warn patients against excessive intake [2]. Insulin and insulin secretagogues raise hypoglycemia risk, and the label says lower doses of those drugs may be needed [2].
Intravascular iodinated contrast is the other one to know. The label says to stop metformin at the time of, or before, the imaging procedure in patients with an eGFR between 30 and 60, a history of hepatic impairment, alcoholism or heart failure, or when intra-arterial contrast is used; it says to re-evaluate eGFR 48 hours later and restart metformin if renal function is stable [2].
Kidney function: metformin's rules, and alirocumab's lack of them
The metformin label calls for an eGFR before starting and at least yearly afterward. It is contraindicated below 30 mL/min/1.73 m2, starting is not recommended between 30 and 45, and if eGFR later falls below 45 the label says to assess benefit and risk of continuing and to discontinue below 30 [2]. The Praluent label says no dose adjustment is needed for renal impairment or for mild to moderate hepatic impairment [1].
The practical answer
Neither the metformin label nor the Praluent label treats the other drug as an interaction, and neither describes spacing the doses apart [1][2]. The metformin label says to take immediate-release tablets with meals [2]. The Praluent label sets the injection schedule at every 2 weeks or every 4 weeks [1].
What each label does ask for is separate monitoring: an eGFR at least yearly and vitamin B12 at 2 to 3 year intervals on metformin, and, per the Praluent label, an LDL cholesterol measurement that can be done as early as 4 weeks after starting alirocumab [1][2].
Questions worth asking
Frequently asked questions
Do Praluent and metformin interact?
Do the two drugs need to be timed apart?
Which blood tests does each label call for?
What are metformin's most important interactions?
What happens if kidney function declines while taking both?
Does alirocumab have significant drug interactions of its own?
References
Show all 4 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Metformin hydrochloride tablets (Granules, immediate-release) prescribing information. Metformin hydrochloride tablets (Granules, immediate-release) label
- Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107.
- U.S. National Library of Medicine, DailyMed. Metformin hydrochloride extended-release tablets (Sun) prescribing information. Metformin hydrochloride extended-release tablets (Sun) label